{"id":"W4311220073","doi":"10.1007/s13555-022-00861-4","title":"Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"LEO Pharma; UCB Pharma; Regeneron Pharmaceuticals; Sun Pharma; Valeant Pharmaceuticals International; Case Western Reserve University; XBiotech; Celgene; Incyte; Dermira; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Term (time); Quality of life (healthcare); Internal medicine; Dermatology; Adalimumab; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004619266,0.001182947,0.002694606,0.0003865258,0.0004362705,0.001242832,0.0006852827,0.001740809,0.002619041],"category_scores_gemma":[0.003122847,0.0006207724,0.004787284,0.0005900777,0.001112693,0.0008461528,0.0006123696,0.002531887,0.0004314303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00106117,"about_ca_system_score_gemma":0.0009395324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001041188,"about_ca_topic_score_gemma":0.001305327,"domain_scores_codex":[0.9979913,0.001183634,0.0001742313,0.000227916,0.0001908806,0.000232157],"domain_scores_gemma":[0.9976349,0.0006676773,0.0008059849,0.0001995168,0.0001531503,0.0005387616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9568565,0.007020012,0.005802326,0.0008100851,0.003342698,0.00006118281,0.0001388624,0.0004029689,0.00295616,0.00003014163,0.0003924604,0.02218663],"study_design_scores_gemma":[0.8071257,0.1530294,0.03586495,0.00008951437,0.002325502,0.00008664586,0.00005151032,0.0003028696,0.0004904789,0.00008592691,0.0005151374,0.00003248234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921581,0.005652925,0.0002018285,0.0001958526,0.00008516829,0.0007884415,0.0004413089,0.00001934869,0.000456957],"genre_scores_gemma":[0.9947346,0.001914988,0.0003940976,0.0003779019,0.0001465282,0.001246918,0.0007998631,0.00000693257,0.000378043],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004619266,"threshold_uncertainty_score":0.02442932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03323950638803691,"score_gpt":0.288253045115014,"score_spread":0.2550135387269771,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}